← Every company
AstraZeneca PLC Lobbying
What AstraZeneca PLC discloses spending to lobby Congress, and who it pays to do it. Every lobbying firm files quarterly under the Lobbying Disclosure Act, naming its client, its fee and the issues it worked.
AZN on carbonthat →Disclosed spend
$4.6M
across every filing on file
Filings
11
Years covered
1
Firms retained
4
What it lobbies about
Medicare/MedicaidHealth IssuesPharmacyCopyright/Patent/TrademarkTariff (miscellaneous tariff bills)Trade (domestic/foreign)
11 filings
Newest year first, and within a year the largest fee first — a filing period is a word rather than a date, so it cannot order itself.
| Period | Lobbying for them | Disclosed |
|---|---|---|
| 20261st Quarter (Jan 1 - Mar 31) | ASTRAZENECA PHARMACEUTICALS LPHealth IssuesMedicare/Medicaid | $2.3M |
| 20262nd Quarter (Apr 1 - June 30) | ASTRAZENECA PHARMACEUTICALS LPHealth IssuesMedicare/Medicaid | $1.7M |
| 20261st Quarter (Jan 1 - Mar 31) | W STRATEGIES, LLCMedicare/Medicaid | $80K |
| 20262nd Quarter (Apr 1 - June 30) | TODD STRATEGY GROUPHealth IssuesMedicare/Medicaid | $80K |
| 20262nd Quarter (Apr 1 - June 30) | TARPLIN, DOWNS & YOUNG, LLCBudget/AppropriationsMedicare/Medicaid | $80K |
| 20261st Quarter (Jan 1 - Mar 31) | TODD STRATEGY GROUPMedicare/MedicaidHealth Issues | $80K |
| 20262nd Quarter (Apr 1 - June 30) | TIBER CREEK GROUPHealth IssuesForeign Relations | $80K |
| 20261st Quarter (Jan 1 - Mar 31) | TARPLIN, DOWNS & YOUNG, LLCBudget/AppropriationsMedicare/Medicaid | $80K |
| 20262nd Quarter (Apr 1 - June 30) | W STRATEGIES, LLCMedicare/Medicaid | $80K |
| 20261st Quarter (Jan 1 - Mar 31) | TIBER CREEK GROUPMedicare/MedicaidHealth Issues | $80K |
| 20263rd Quarter (July 1 - Sep 30) | THOLOS GOVERNMENT RELATIONSPharmacyCopyright/Patent/Trademark | — |
A filing reports either the fee paid to a lobbying firm or what a company spent lobbying for itself, never both, so the total is a sum of the two. The client is named as filed, which is often a subsidiary. Lobbying is lawful, disclosed and extremely common — the figure is context, not an accusation.
More on AZN
Company overviewEverything on AZN in one place, with the price.SEC filingsWhat AZN's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat AZN's own officers and directors buy and sell.Who lobbies for itThe lobbyists on AZN's account, and who they worked for.Federal contractsWhat federal agencies pay AZN.PatentsWhat AZN is filing at the patent office.Workplace safetyWhat OSHA found at AZN's sites.